文献速递白血病淋巴瘤

Umbralisib联合伊布替尼治疗复发或难治性慢性淋巴细胞白血病或套细胞淋巴瘤:一项多中心1-1b期研究

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
PubMed 文献 · Lancet Haematol · 2018-12-14

这项研究者发起的多中心1-1b期研究纳入44例复发或难治性慢性淋巴细胞白血病或套细胞淋巴瘤患者,其中42例至少接受一剂研究药物。Umbralisib联合伊布替尼耐受良好且具有活性,未达到最大耐受剂量,推荐的2期剂量为Umbralisib 800 mg每日一次。

要点

  • Umbralisib联合伊布替尼在复发或难治性CLL或MCL中耐受良好且具有活性。
  • 未观察到剂量限制性毒性,未达到最大耐受剂量。
  • 推荐的2期剂量为Umbralisib 800 mg每日一次联合伊布替尼。

核心结论

  • Umbralisib联合伊布替尼在复发或难治性慢性淋巴细胞白血病和套细胞淋巴瘤中耐受良好且具有活性,推荐的2期剂量为Umbralisib 800 mg每日一次。
  • 据作者所知,这是BTK抑制剂与PI3K-δ抑制剂双药联合在B细胞恶性肿瘤中的首次临床数据,结果提示该方法可行且值得进一步研究。

研究设计与样本

  • 研究者发起的多中心1-1b期研究,来自美国五个学术和社区中心。
  • 纳入44例患者,其中42例至少接受一剂研究药物(慢性淋巴细胞白血病n=21;套细胞淋巴瘤n=21)。
  • 患者年龄≥18岁,ECOG体能状态≤2,接受Umbralisib口服每日一次(400 mg、600 mg或800 mg)联合伊布替尼口服每日一次(慢性淋巴细胞白血病420 mg或套细胞淋巴瘤560 mg),直至疾病进展或不可耐受毒性。
  • 1期剂量递增队列按组织学独立采用标准3×3设计。
  • 主要终点为意向性治疗评估最大耐受剂量、安全性和剂量限制性毒性。

主要发现

  • 2014年12月5日至2018年3月7日入组44例患者,其中42例至少接受一剂研究药物(慢性淋巴细胞白血病n=21;套细胞淋巴瘤n=21)。
  • 患者中位年龄68岁(范围48-85),中位既往治疗线数2(IQR 1-3)。
  • 未观察到剂量限制性毒性,未达到Umbralisib的最大耐受剂量。
  • 与伊布替尼联合时Umbralisib推荐的2期剂量为800 mg每日一次。
  • 最常见不良事件包括腹泻(22例[52%]患者,其中10%为3级)、感染(21例[50%],17%为3-4级)和转氨酶升高(10例[24%],2%为3级)。

关键数值与推荐

  • Umbralisib联合伊布替尼时推荐的2期剂量为Umbralisib 800 mg每日一次。
  • 伊布替尼剂量为慢性淋巴细胞白血病420 mg每日一次或套细胞淋巴瘤560 mg每日一次。

临床怎么用

  • 作者认为Umbralisib联合伊布替尼在复发或难治性慢性淋巴细胞白血病和套细胞淋巴瘤中耐受良好且具有活性。
  • 作者认为该BTK抑制剂与PI3K-δ抑制剂双药联合方法可行且值得进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with relapsed or refractory high-risk chronic lymphocytic leukaemia or mantle cell lymphoma often do not derive durable benefit from ibrutinib monotherapy. We hypothesised that dual B-cell receptor pathway blockade would be tolerable and efficacious. We investigated a next-generation phosphoinositide-3-kinase-δ inhibitor (PI3K-δi), umbralisib, plus a Bruton tyrosine kinase inhibitor (BTKi), ibrutinib, in relapsed or refractory chronic lymphocytic leukaemia and mantle cell lymphoma. METHODS: We did an investigator-initiated, multicentre, phase 1-1b study of patients from five sites in the USA (academic and community sites). Patients were 18 years and older with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma, with an Eastern Cooperative Oncology Group performance status of 2 or less, and were given umbralisib orally once daily (400 mg, 600 mg, or 800 mg) and ibrutinib orally once daily (420 mg for chronic lymphocytic leukaemia or 560 mg for mantle cell lymphoma) until disease progression or unacceptable toxicity. The phase 1 dose-escalation cohorts for each histology escalated independently in a standard 3 × 3 design. The primary endpoints were intention-to-treat assessment of maximum-tolerated dose, safety, and dose-limiting toxicities. This trial is ongoing and is registered with ClinicalTrials.gov, number NCT02268851. FINDINGS: Between Dec 5, 2014, and March 7, 2018, we enrolled 44 patients, of which 42 were given at least one dose of study drug (chronic lymphocytic leukaemia, n=21; mantle cell lymphoma, n=21). Patients had a median age of 68 years (range 48-85) and had a median of two (IQR 1-3) previous therapies. No dose-limiting toxicities were observed and the maximum-tolerated dose of umbralisib was not reached. The recommended phase 2 dose of umbralisib when given in combination with ibrutinib was 800 mg once daily. The most frequent adverse events included diarrhoea (22 [52%] patients, 10% of whom had grade 3), infection (21 [50%], 17% grade 3-4), and transaminitis (ten [24%], 2% grade 3). Serious adverse events occurred in 12 (29%) patients and included lipase elevation, atrial fibrillation, hypophosphataemia, adrenal insufficiency, transaminitis, and infections. INTERPRETATION: Umbralisib plus ibrutinib is well tolerated and active in relapsed or refractory chronic lymphocytic leukaemia and mantle cell lymphoma, with a recommended phase 2 dose of umbralisib 800 mg once daily. To the best of our knowledge, these are the first clinical data on a BTKi and PI3K-δi doublet in B-cell malignancies, and the results suggest that this approach is feasible and worthy of further study. FUNDING: TG Therapeutics, Leukemia and Lymphoma Society Therapy Accelerator Program.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Davids MS, Kim HT, Nicotra A, et al. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. Lancet Haematol. 2018. PMID: 30558987. doi:10.1016/S2352-3026(18)30196-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。